Study | Age | gender | Symptoms | Tumor | LH (mIU/mL) | a-subunit (ng/ml) | FSH (mIU/mL) | E2(pg/ml) | T (ng/ml) | Medical therapy | Operation |
---|---|---|---|---|---|---|---|---|---|---|---|
Peterso [2] | 30 | Male | azzospermic | Intrasellar mass | 207 (6–26) | 72(< 0.5–2.5) | 2(normal range 5–25) | 110(< 10–60) | 1500 (300–1000) | TRH, LRH, L-dopa, metyrapone, | Transsphenoidal operation |
Klibanski [3] | 48 | Male | Increase in libido, blind | Pituitary tumor | 99 (2–18) | 5.7(< 2.5) | 5.5(−) | 219(< 52) | 1660 (300–1100) |  | Transfrontal craniotomy |
Vos [4] | 20 | Male | Grand-mal seizures | Hypothalamic-pituitary tumor | 140 (2–15) | 9105 (3–30) | 4 (3–12) |  | 53 (12–30) | SMS201–995 | Transsphenoidal operation |
Castelo-Branco [5] | 31 | Female | OHSS | Pituitary macroadenoma | 4.9(−) |  | 7.2(−) |  |  | Prolactin, cabergoline, somatostatin | Transsphenoidal operation |
Roman [6] | 33 | Male | Testicular pain, dysuria | Intrasellar mass | 207 (3–9) | 72(< 0.5–2.5) | 2 (4–11) |  | 15,000 (30000–80,000) | LHRH | Transsphenoidal operation |
Kadakia [7] | 9 | Male | Precocious puberty | Anterior pituitary tumor | 5(< 0.49) |  | < 0.05 (0.87–9.16) |  | 44,200(< 4200) | leuprolide | Transsphenoidal operation |